ADDF reflects on Eli Lilly’s donanemab
Company’s phase 3 research showed the importance of running biomarker-powered clinical trials
Read More
Tag: donanemab
Lilly’s donanemab slows decline in Phase II Alzheimer’s study
Alzheimer’s Drug Discovery Foundation says results are ‘promising’
Read More
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
- Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
- Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
